ESPE Abstracts

Introduction: Central precocious puberty (CPP) is typically treated with gonadotropin-releasing hormone (GnRH) agonists. Although there are numerous GnRH agonist variants available, there is limited research comparing the timing of menarche in girls treated with monthly (3.75 mg) versus 3-monthly (11.25 mg) Leuprolide acetate. The objective of this study was to evaluate the timing of menarche after the administration of monthly and 3-monthly Leuprolide acetate.

Methods: This study involved 86 girls diagnosed with CPP based on GnRH stimulation tests. A total of 60 girls received a monthly intramuscular dose of 3.75 mg of Leuprolide acetate, while the remaining 26 girls received Leuprolide acetate at a dosage of 11.25 mg intramuscularly every 3 months. The time from completion of treatment to the onset of menarche, as well as the level of LH suppression at 6 months of Leuprolide acetate therapy, were evaluated.

Results: After discontinuation of treatment, the average time until menarche was found to be comparable between the monthly and 3-monthly treatment groups (11.28 ± 7.2 and 10.15 ± 7.9 months, p-value 0.27). Significantly greater LH suppression (2.76 ± 1.9 and 1.84 ± 0.9 IU/L, P -value 0.02) was observed with 3-monthly Leuprolide acetate.

Conclusion: The interval between the end of treatment and the start of menarche was shown to be comparable between the monthly and 3-monthly Leuprolide acetate treatment groups.